Alkem Laboratories Ltd Q1 FY26 – ₹3,371 Cr Sales, ₹654 Cr PAT, EPS ₹55.6: Anti-Infective King Jo Diabetes Aur Cyber Frauds Dono Ko Manage Kar Raha Hai
1. At a Glance
Quarterly numbers dekh ke lagta hai Alkem ne apne “PAN-D, CLAVAM aur SUMO” brands ki tarah ek dhamaka maara hai — ₹3,371 Cr sales aur ₹654 Cr PAT, matlab profit var 20% se zyada. EPS ₹55.6, jo investor ke portfolio mein ekdum “UPRISE-D3” jaise kaam kar raha hai. Par saath mein cyber-fraud aur GST demand orders bhi aa gaye — matlab yeh pharma nahi, ek Netflix thriller hai.
2. Introduction
Alkem ekdum “5th largest pharma company of India” ban ke baitha hai — 4.1% domestic market share, anti-infectives mein #1. Matlab agar India mein infection hui, chances high hain ki dawa Alkem ki hi hoga.
Brands ki line-up toh Bollywood ke “100 Crore Club” se zyada sorted hai — PAN-D, CLAVAM, GEMCAL, SUMO, A-to-Z, CHERI… list aisi hai jaise ek doctor ke prescription pad ki IPL team. Aur ab inhone diabetes drug Empagliflozin ka generic “Empanorm” launch kiya at 80% discount. Matlab doctor prescribe karega aur patient bolega — “Bhai yeh toh buy one get four free lag raha hai.”
Global mein bhi dhoom — US mein ANDA approvals ke dher, 750+ dossiers approve ho chuke. Aur biosimilars mein out-licensing agreements chal rahe UK-Switzerland-Brazil mein. Matlab ekdum “pharma outsourcing ka Zomato.”
Par picture perfect nahi hai: GST demand ₹69 Cr ka, cyber security breach US subsidiary mein, aur promoter holding ghatt ke 53% ho gayi. Matlab governance ka thoda “karela with neem” taste bhi milta hai.
3. Business Model – WTF Do They Even Do?
Alkem ka business simple lagta hai, lekin detail mein jao toh ekdum buffet hai:
Domestic Formulations (70% revenue): Yeh asli paisa printing machine hai. Anti-infectives aur gastro mein top ranks, chronic therapy expansion (neuro, cardiac, diabetes) chal raha hai. India mein 12,500+ field force, 8,400+ stockists, matlab agar ek chemist shop kholo toh chance hai Alkem ka salesman pehle din hi aa jaayega.
International (30% revenue):
Generics: US mein ANDAs ke pile.
Biosimilars: 7 biosimilars out-licensing, pharma ke “royalty wala” model.
BioCDMO: Contract manufacturing for biologics, matlab abhi “pharma ka Foxconn” bhi ban raha hai.
Brands: 17 brands ₹100 Cr+ club mein, 3 brands ₹500 Cr+ mega stars. Basically Alkem ka P&L ek Bollywood masala movie jaisa hai — har genre covered.
Soch ke dekho: anti-infectives se chronic ka shift exactly waise hai jaise ek actor comedy se OTT serious role pe switch kare. Patient aur investor dono confuse, par business chal raha hai.
4. Financials Overview
Quarterly Performance (₹ Cr)
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
3,371
3,032
3,144
+11.2%
+7.2%
EBITDA
739
609
391
+21.3%
+88.9%
PAT
654
550
322
+19.9%
+103.1%
EPS (₹)
55.6
45.6
25.6
+21.9%
+117.2%
Commentary: Sales growth ekdum “Indian wedding buffet” jaisa — thoda overload. PAT margin jump karke 19.4% aa gaya. QoQ profit double se zyada hua, jo investors ke liye dopamine injection hai. P/E abhi 29× chal raha hai, industry average 33×. Matlab thoda premium, par Cipla aur Sun Pharma ke comparison mein abhi “middle class” valuation.
Tumhare hisaab se — yeh margin jump sustainable hai ya bas ek “quarterly jugaad” tha?
